FilingReader Intelligence
Hengrui Medicine gets clinical trial approval for two drugs
August 13, 2025 at 05:07 PM UTC•By FilingReader AI
Jiangsu Hengrui Medicine's subsidiaries received clinical trial approval for SHR-A2102 and Adberlimab injection. SHR-A2102 is an ADC targeting Nectin-4, with cumulative R&D investment of 205.47m yuan. Adberlimab, a PD-L1 monoclonal antibody, had R&D investment of 90.13m yuan.
The trials will evaluate the drugs in recurrent/metastatic head and neck squamous cell carcinoma.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime